The role of angiogenesis in neuroendocrine tumors

Endocrinology and Metabolism Clinics of North America

Volumn 39, Issue 4, 2010, Pages 839-852

  Lyons, John ^a   Anthony, Catherine T ^a   Woltering, Eugene A ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Human in vitro modeling; I MTOR inhibitors; Platelet derived growth factor (PDGF); Somatostatin receptors; Vascular endothelial growth factor (VEGF)

Indexed keywords

2 METHOXYESTRADIOL; ANGIOGENESIS INHIBITOR; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; COLCHICINE; ENDOSTATIN; ERYTHROPOIETIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEFITINIB; HEPARIN; HYDROCORTISONE SODIUM PHOSPHATE; IMATINIB; INTERFERON; OCTREOTIDE; PACLITAXEL; PASIREOTIDE; RECOMBINANT ALPHA2B INTERFERON; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN DERIVATIVE; SORAFENIB; TEMOZOLOMIDE; UNINDEXED DRUG; VAPREOTIDE; VATALANIB; VINBLASTINE; VINCRISTINE;

BINDING AFFINITY; CANCER INHIBITION; CARCINOID; CELL GROWTH; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; GOUT; HUMAN; LIVER METASTASIS; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; TREATMENT RESPONSE; TUMOR CELL; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

ANIMALIA;

EID: 78649347941     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.08.006     Document Type: Review

References (50)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29(6 Suppl 16):15-18.
2. Krulich L., Dhariwal A.P., McCann S.M. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology 1968, 83(4):783-790.
3. Pless J., Bauer W., Briner U., et al. Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol Suppl 1986, 119:54-64.
4. Gorden P., Comi R.J., Maton P.N., et al. NIH Conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989, 110(1):35-50.
5. Fassler J.A., O'Dorisio T.M., Stevens R.E., et al. Are somatostatin analogues anti-angiogenic?. Clin Res 1988, 36:869A.
6. Woltering E.A., Barrie R., O'Dorisio T.M., et al. Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 1991, 50(3):245-251.
7. Folkman J. Proceedings: tumor angiogenesis factor. Cancer Res 1974, 34(8):2109-2113.
8. Crum R., Szabo S., Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985, 230(4732):1375-1378.
9. Ingber D.E., Madri J.A., Folkman J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology 1986, 119(4):1768-1775.
10. Barrie R., Woltering E.A., Hajarizadeh H., et al. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 1993, 55(4):446-450.
11. Woltering E.A., Watson J.C., Alperin-Lea R.C., et al. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 1997, 15(1):77-86.
12. Patel P.C., Barrie R., Hill N., et al. Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery 1994, 116(6):1148-1152.
13. Sharma C., Alperin-Lea R.C., Johnson M.A., et al. Inhibition of octreotide acetate (o-a) on proliferation of porcine coronary artery smooth muscle, endothelium and fibroblasts cells. FASEB J 1995, 9(3). [abstract].
14. Danesi R., Agen C., Benelli U., et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 1997, 3(2):265-272.
15. Nicosia R.F., Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 1990, 63(1):115-122.
16. Woltering E.A., Lewis J.M., Maxwell P.J., et al. Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs. Ann Surg 2003, 237(6):790-798. [discussion: 798-800].
17. Watson J.C., Redmann J.G., Meyers M.O., et al. Breast cancer increases initiation of angiogenesis without accelerating neovessel growth rate. Surgery 1997, 122:509-514.
18. Watson J.C., Balster D.A., Gebhardt B.M., et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 2001, 85(2):266-272.
19. Gulec S.A., Woltering E.A. A new in vitro assay for human tumor angiogenesis: three-dimensional human tumor angiogenesis assay. Ann Surg Oncol 2004, 11(1):99-104.
20. Gulec S.A., Drouant G.J., Fuselier J., et al. Antitumor and antiangiogenic effects of somatostatin receptor-targeted in situ radiation with 111In-DTPA-JIC 2DL. J Surg Res 2001, 97(2):131-137.
21. Stafford S.J., Schwimer J., Anthony C.T., et al. Colchicine and 2-methoxyestradiol inhibit human angiogenesis. J Surg Res 2005, 125(1):104-108.
22. LaValee T.M., Zhan X.H., Herbstritt C.J., et al. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors a and b. Cancer Res 2002, 62(13):3691-3697.
23. Seegers J.C., Lottering M.L., Grobler C.J.S., et al. The mammalian metabolite 2-methoxyestradiol affects p53 levels and apoptosis induction in transformed cells but not normal cells. J Steroid Biochem Mol Biol 1997, 62(4):253-267.
24. Fotsis T., Zhang Y., Pepper M.S., et al. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature 1994, 368(6468):237-239.
25. Schumacher G., Kataoka M., Roth J.A., et al. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 1999, 5(3):493-499.
26. Kvols L.K., Reubi J.C. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol 1993, 32:197-201.
27. Lyons J.M., Schwimer J.E., Anthony C.T., et al. The role of VEGF pathways in human physiologic and pathologic angiogenesis. J Surg Res 2010, 159(1):517-527.
28. Hamburger A.W., Salmon S.E. Primary bioassay of human tumor stem cells. Science 1977, 197(4302):461-463.
29. Von Hoff D.D., Clark G.M., Stogdill B.J., et al. Prospective clinical trial of a human tumor cloning system. Cancer Res 1983, 43:1926-1931.
30. Kern D.H., Weisenthal L.M. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990, 82:582.
31. Yao J.C., Phan A., Hoff P.M., et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008, 26(8):1316-1323.
32. Raymond E., Niccoli-Sire P., Bang Y., et al. Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). ASCO Gastrointestinal Cancers Symposium 2010, [abstract]. Available at:, Accessed April 20, 2010. http://www.asco.org/ASCOv2/Meetings/Abstracts%3F%26vmview%3Dabst_detail_view%26confID%3D72%26abstractID%3D1797.
33. Kulke M.H., Lenz H.J., Meropol N.J., et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008, 26(20):3403-3410.
34. Venook A.P., Ko A.H., Tempero M.A., et al. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol 2008, 26(15S):15545. [abstract].
35. Kulke M., Chan J.A., Meyerhardt J.A., et al. Phase II study of 2-methoxyestradiol (2ME2) administered in combination with bevacizumab, in patients (Pts) with advanced carcinoid tumors. ASCO Gastrointestinal Cancers Symposium 2008, [abstract]. Available at:, Accessed April 20, 2010. http://www.asco.org/ascov2/Meetings/Abstracts%3F%26vmview%3Dabst_detail_view%26confID%3D53%26abstractID%3D10528.
36. Kulke M.H., Stuart K., Enzinger P.C., et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006, 24(3):401-406.
37. Yao J.C., Zhang Y.X., Rashid A., et al. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res 2007, 13(1):234-240.
38. Gross D.J., Munter G., Bitan M., et al. Israel glivec in solid tumors study group. The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer 2006, 13(2):535-540.
39. Kulke M.H., Bergsland E.K., Ryan D.P., et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006, 24(22):3555-3561.
40. Anthony L., Chester M., Michael S., et al. Phase II open-label clinical trial of vatalanib (PTK/ZK) in patients with progressive neuroendocrine cancer. J Clin Oncol 2008, 26(Suppl 20):14624. [abstract].
41. Sung M.W., Kvols L., Wolin E., et al. PhaseII proof-of-concept study of atiprimod in patients with advanced low-to intermediate-grade neuroendocrine carcinoma. J Clin Oncol 2008, 26(Suppl 20):4611. [abstract].
42. Hobday T.J., Holen K., Donehower R., et al. A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol 2006, 24(18S):4043. [abstract].
43. Hobday T.J., Rubin J., Holen K., et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a phase II consortium (P2C) study. J Clin Oncol 2007, 25(18S):4504. [abstract].
44. Kulke M., Blaszkowski L.S., Zhu A.X., et al. PhaseI/II study of everolimus (RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET). ASCO Gastrointestinal Cancers Symposium 2010, [abstract]. Available at:, Accessed April 20, 2010. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2350.
45. Yao J.C., Phan A., Chang D.Z., et al. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET). J Clin Oncol 2007, 25(18S):4503. [abstract].
46. Kvols L., Wiedenmann B., Oberg K., et al. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study. J Clin Oncol 2006, 24(18S):4082. [abstract].
47. Faiss S., Pape U.F., Böhmig M., et al. International lanreotide and interferon alfa study group. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the international lanreotide and interferon alfa study group. J Clin Oncol 2003, 21(14):2689-2696.
48. Rinke A., Müller H.H., Schade-Brittinger C., et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009, 27(28):4656-4663.
49. Brizzi M.P., Berruti A., Ferrero A., et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the piemonte oncology network. BMC Cancer 2009, 9:388.
50. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006, 24(3):401-406.